comparemela.com

Latest Breaking News On - Nathalie ponnier - Page 9 : comparemela.com

Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury

Press release content from Business Wire. The AP news staff was not involved in its creation.

John neylanVifor pharmaJulien vignotKlaus henning jensenNathalie ponnierExchange commission onSwiss stock exchangeGlobal head corporate communicationsAngion biomedica corpSwiss exchangeExchange commissionVifor pharma groupFresenius medical careAngion biomedicaEstimated glomerular filtration rateChief medical officer

Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211209006035/en/ AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma

United statesJohn neylanVifor pharmaJulien vignotKlaus henning jensenNathalie ponnierExchange commission onSwiss stock exchangeGlobal head corporate communicationsAngion biomedica corpSwiss exchangeExchange commissionVifor pharma groupFresenius medical careRegulatory newsAngion biomedica

Vifor Pharma: First patient enrolled in phase-IIa study of vamifeport in patients with sickle cell disease

Vamifeport (VIT-2763) is the first oral ferroportin inhibitor investigated for treatment of diseases with ineffective production of red blood cells and iron overload such as sickle cell disease

United statesUnited kingdomVifor pharmaJulien vignotKlaus henning jensenNathalie ponnierSwiss stock exchangeDrug administrationGlobal head corporate communicationsSwiss exchangeVifor pharma groupEuropean medicines agencyFresenius medical careChief medical officerPharma groupVifor fresenius medical care renal pharma

Vifor Pharma appoints Hervé Gisserot as new Chief Commercial Officer and member of the Executive Committee

Hervé Gisserot will join Vifor Pharma as Chief Commercial Officer on 17 January 2022 Responsibilities of Sales, Marketing and Market Access to be streamlined under Chief Commercial Officer

France generalVifor pharmaJulien vignotAbbas hussainAsia pacificNathalie ponnierInstitute of political science parisSwiss stock exchangeGlobal head corporate communicationsSwiss exchangeVifor pharma executive committeeVifor pharma groupFresenius medical careChief commercial officerMarket accessPharma group

Vifor Pharma Group: Vifor Pharma comments on market speculations

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Due to current market speculations, Vifor Pharma Group states the following: Vifor Pharma Group systematically reviews options that

Vifor pharmaJulien vignotNathalie ponnierSwiss stock exchangeVifor pharma groupGlobal head corporate communicationsSwiss exchangeFresenius medical careRegulatory newsPharma groupVifor fresenius medical care renal pharmaHead corporate communicationsInvestor relations

vimarsana © 2020. All Rights Reserved.